Beckman Coulter Conducting Educational Presentations To Support Women’s Health In The UAE

Beckman Coulter, a global leader in clinical diagnostics, announced today that it is conducting a series of grand rounds presentations focused on improving overall wellness for women in the United Arab Emirates (UAE), the Kingdom of Saudi Arabia and Egypt. Events are currently scheduled to occur across the UAE, as well as in Jeddah, Saudi Arabia and Cairo, Egypt. The main topics of these discussions are focused on what healthcare providers can do to help address some of the challenges facing Emirati women today, including cardiovascular disease and infertility.

According to the World Health Organization, cardiovascular diseases are the number one cause of death globally, with more people dying from cardiovascular diseases each year than any other cause.¹ Regarding infertility, a study conducted by the Dubai Health Authority (DHA) found that around 50 percent of women in the UAE face issues. Statistics from the same study also showed that in Dubai alone, the incidence of infertile women seeking treatment per year could nearly double from 5,975 cases in 2015 to 9,139 cases by 2030.

Beckman Coulter is conducting these educational presentations as part of its ongoing commitment to advancing healthcare for every person by driving awareness of the clinical laboratory’s role in improving healthcare outcomes. During the roadshow, Beckman Coulter will showcase its diagnostic solutions geared toward enhancing healthcare services for women in the following areas:

• Cardiovascular health: Beckman Coulter’s Access hsTnI assay incorporates state-of-the-art sensitivity that enables it to detect previously undetectable levels of cardiac troponin in order to help identify ongoing ischemia and myocardial injury (AMI) earlier.² It also helps to improve a clinicians’ confidence in identifying the rise and/or fall in troponin values characteristic of AMI for early detection of cTnl in the bloodstream.³ While the Access hsTnI assay offers detection values for the total patient population, it also provides gender-specific cut-offs, ensuring clinicians can reference the appropriate value ranges for their specific patient. This is particularly important for women because they are 10 times more likely to die of cardiovascular disease than e.g. breast cancer. And, of the total population of people who die of cardiac injury, 64% are women.⁴
• Reproductive Health/Infertility: Anti-Müllerian Hormone (AMH) has become an increasingly important factor in monitoring reproductive health, which has led to the evolution of tests with increasing sensitivity for expanding diagnostic applications. Beckman Coulter is the market innovator of AMH assays, having introduced the first ELISA AMH assay and the first automated AMH tests. Because Beckman Coulter AMH assays have been studied extensively, the company has played an important role in establishing the acceptance of AMH testing in the field of fertility. The automated Access AMH assay aids healthcare providers to assess a woman’s ovarian reserve and helps guide the clinical management of women planning to become pregnant at a later stage in life or struggling with infertility, because it can be used to individualize a patient-care strategy for controlled ovarian stimulation (COS). Knowing one’s AMH values can reveal which patients are unlikely to respond to IVF and which might be at risk of ovarian hyperstimulation syndrome (OHSS), which can be potentially fatal.⁵

During the grand rounds events, Beckman Coulter will also highlight its full portfolio of reproductive health solutions including Sensitive Estradiol, as well as focus on reproductive endocrinology and prenatal screening assays and bone metabolism which help tackle a range of conditions and improve testing confidence with standardization and automation.